FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
Fate Therapeutics
Eli Lilly and Company
Tizona Therapeutics, Inc
Eli Lilly and Company
Fate Therapeutics
NKGen Biotech, Inc.